JUPITER lights up New Orleans sky

January 2009
CMAJ: Canadian Medical Association Journal;1/6/2009 Conference Reports, p3
Academic Journal
The article offers information on developments and updates on tools and methods in assessing and managing cardiovascular risk. The American Heart Association released the therapeutic use of statin and the use of high-sensitivity C-reactive protein. It is mentioned that the use of statin can reduce the prevalence of cardiovascular events in patients with normal cholesterol levels but have an elevated high-sensitivity C-reactive protein. Updates on the result of Justification for the Use of Statins in Prevention: an Intervention Trial Evaluation Rosuvastin (JUPITER) are presented.


Related Articles

  • Assessing cardiac risk factors: is a rethink in order?  // CMAJ: Canadian Medical Association Journal;1/6/2009 Conference Reports, p1 

    The article offers information on developments and updates on tools and methods in assessing and managing cardiovascular risk. The American Heart Association released the risk markers and appropriate use of statins. It is argued that the use of statin can reduce the prevalence of cardiovascular...

  • National Trends in Statin Use by Coronary Heart Disease Risk Category. Jun Ma; Sehgal, Niraj L.; Ayanian, John Z.; Stafford, Randall S. // PLoS Medicine;May2005, Vol. 2 Issue 5, p434 

    Background Only limited research tracks United States trends in the use of statins recorded during outpatient visits, particularly use by patients at moderate to high cardiovascular risk. Methods and Findings Data collected between 1992 and 2002 in two federally administered surveys provided...

  • Early, Intensive and Long-term Statin Therapy in Acute Coronary Syndrome: Focus on Anti-inflammatory Mechanisms. Jian-Jun Li; Sheng-Shou Hu // Vascular Disease Prevention;Jul2005, Vol. 2 Issue 3, p181 

    An acceptable concept is that the acute coronary syndrome (ACS) is related to erosion or rupture of vulnerable plaques leading to intracoronary thrombosis as a result of the activation of the coagulation cascade and platelet aggregation. Clinical trials and animal models suggest an inflammatory...

  • STATlN THERAPY, C-REACTIVE PROTEIN LEVELS, AND RISK OF FUTURE ADVERSE CORONARY EVENTS: A PROSPECTIVE OBSERVATIONAL STUDY. Russell, C. J. H.; Exley, A. R.; Buckenham, S. J.; Jarrett, E. J.; Marshall, C. J.; Charman, S. C.; Bennett, M. R.; Shapiro, L.; Ritchie, A. J. // Heart;May2004 Supplement 3, Vol. 90, pA13 

    This article presents a study on station therapy, AC-reactive protein levels, and risk of future adverse coronary events. Clinical trials of statin therapy report reductions in morbidity and mortality exceeding that predicted by the actual reduction in serum lipid achieved. These findings...

  • New Suspect, CRP, Joins Cholesterol in Cardiac Risks.  // Tufts University Health & Nutrition Letter;Mar2005, Vol. 23 Issue 1, p1 

    Reports that C-reactive protein (CRP) was considered a risk factor for heart disease according to the findings of studies by researchers at the Cleveland Clinic and at Boston's Brigham and Women's Hospital, both published in the "New England Journal of Medicine." Use of statin therapy to reduce...

  • High-sensitive factor I and C-reactive protein based biomarkers for coronary artery disease. Qing Zhao; Jian-Shi Du; Dong-Mei Han; Ying Ma // International Journal of Clinical & Experimental Medicine;2014, Vol. 7 Issue 12, p5158 

    An analysis of high-sensitive factor I and C-reactive proteins as biomarkers for coronary artery disease has been performed from 19 anticipated cohort studies that included 21,567 participants having no information about coronary artery disease. Besides, the clinical implications of statin...

  • Effective Lipid-lowering Therapy in High-risk Patients. Arsenault, Benoit J.; Kastelein, John J. P.; Tardif, Jean-Claude // European Journal of Cardiovascular Medicine;Sep2010, Issue 3, p2 

    Cardiovascular disease (CVD) is the primary cause of mortality in developed and developing societies. Identifying patients at high CVD risk is important but challenging. Measurement of classical risk factors is crucial for this assessment. Also, next to traditional factors such as lipids or...

  • Latest Heart News: the good, the bad, and the not so bad.  // HealthFacts;Dec2007, Vol. 32 Issue 12, p1 

    This article explains that the prescription-only cholesterol-lowering statin drug might soon be sold over the counter. This drug is sold under the brands Lipitor, Mevacor, Crestor, Pravacol and Lescol. People who have no heart disease can also benefit from statin drug and can be given to people...

  • Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond. Auer, J.; Berent, R.; Weber, T.; Eber, B. // Current Medicinal Chemistry;Oct2002, Vol. 9 Issue 20, p1831 

    Statins significantly reduce cardiovascular-related morbidity and mortality in patients with and without coronary artery disease. The potential of this drug class has yet to be fully explored. Accumulating evidence from basic research and clinical trials indicates that statins have pleiotropic...


Read the Article


Sign out of this library

Other Topics